1,414 patients were randomized, with 730 receiving TAVR with either a Medtronic Evolut R, PRO, or CoreValve™ and 684 undergoing surgery. "Results at five years support Evolut's supra-annular ...

Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement, TAVR, system ...

On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. Start Your Mornings Smarter! Wake up with Breakfast ...

Patients were implanted with CoreValve, Evolut R, or Evolut PRO (n = 730; Medtronic) or underwent surgery with a bioprosthetic valve (n = 684). In a separate analysis that excluded patients who were ...

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...

vice president and chief medical officer of Structural Heart, which is part of the Medtronic Cardiovascular Portfolio. "These results reinforce the recently reported Evolut evidence from the SMART ...

Medtronic plc, a global leader in healthcare technology, announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic ...